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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Objectives: To further elucidate which patients with metastatic renal cell carcinoma 
(mRCC) may benefit from cytoreductive nephrectomy (CN) before targeted therapy (TT), 
and to assess the overall survival of patients undergoing CN and TT versus TT alone.
Materials and Methods: We identified 88 patients who underwent CN at our institu-
tion prior to planned TT and 35 patients who received TT without undergoing CN. 
Preoperative risk factors described in the literature were assessed in our patient popu-
lation (serum albumin, liver metastasis, symptomatic metastasis, clinical ≥T3 disease, 
retroperitoneal and supradiaphragmatic lymphadenopathy). Patients were stratified by 
number of pretreatment risk factors and overall survival (OS) was compared.
Results: TT patients had significantly more risk factors compared to CN patients (3.06 
vs. 2.11, p<0.01). Patients who received TT alone had median OS of 5.8 months. All 
but one patient receiving TT alone had two or more risk factors. A comparison of the 
CN and TT groups was performed by constructing Kaplan-Meier curves. There was no 
significant difference in median OS for those patients with exactly two risk factors 
(447 vs. 389 days, p=0.24), and those with three or more risk factors (184 vs. 155 days, 
p=0.87).
Conclusions: Using previously described pretreatment risk factors we found that patients 
with two or more risk factors derived no significant survival advantage from CN in the 
TT era. These risk factors should be incorporated in the assessment of patients for CN.
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INTRODUCTION
Based on the results of two landmark 
randomized controlled trials (1-3), cytoreductive 
nephrectomy (CN) is recommended as a part of 
the treatment for many patients with metastatic 
RCC (mRCC). Multiple studies have addressed ap-
propriate patient selection for CN (4-7). Various 
pretreatment risk factors have been proposed, in-
cluding serum albumin, serum lactate dehydroge-
nase (LDH), retroperitoneal or supradiaphragmatic 
lymphadenopathy, liver metastasis, symptomatic 
metastasis on presentation, and clinical T3 or 
greater disease (6). However, validation of these 
risk factors in an independent data set is lacking, 
especially among those treated with targeted 
therapy (TT) alone. Importantly, previous studies 
included patients who received immunotherapy, 
rather than TT, which is not consistent with con-
temporary practice.
To better determine the benefits of CN in 
the TT era, we retrospectively reviewed patients 
at our institution who received TT alone (TT 
group) or CN followed by planned TT (CN group). 
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We assessed the ability of previously identified 
risk factors (6) to discriminate survival in our 
population. Patients were stratified by the number 
of risk factors present, and the overall survival 
of patients undergoing CN and planned TT was 
compared to those receiving TT alone.
MATERIALS AND METHODS
Patient population
 After Institutional Review Board approval, 
we retrospectively reviewed all mRCC patients 
who received systemic TT from 2005 to 2013 at 
our institution. We defined TT as patients who 
received tyrosine kinase inhibitors (TKI), mam-
malian target of rapamycin (mTOR) inhibitors, or 
vascular endothelial growth factor (VEGF) inhibi-
tors. We identified 100 patients who underwent 
CN at our institution prior to initiation of planned 
TT, and 39 other patients who received TT without 
undergoing CN. Of the CN patients, eight were ex-
cluded due to unavailable pretreatment imaging 
and four were excluded due to missing survival 
data. Of the TT patients, two were excluded due 
to incomplete clinical data and two were excluded 
due to prior immunotherapy. Thus, our final co-
hort consisted of 123 patients: 88 patients who re-
ceived CN and 35 who were treated with TT alone. 
Histologic subtype for the CN patients consisted 
of: 71% clear cell, 17% sarcomatoid, 7% papillary 
type II, 5% other (including collecting duct, chro-
mophobe, and squamous differentiation). Subtype 
classification for the TT alone patients could not 
be determined as all patients were diagnosed ba-
sed on biopsy of their metastatic site, which pre-
sented histologic limitations.
Clinical variables and outcomes
 The following clinical variables were col-
lected: age, adult comorbidity evaluation (ACE) 
score (8), Karnofsky performance status, serum 
albumin, serum lactate dehydrogenase (LDH), cli-
nical T stage, presence of liver metastasis, symp-
tomatic metastasis, and retroperitoneal or supra-
diaphragmatic lymphadenopathy. Clinical T stage 
was based on the 2010 American Joint Committee 
on Cancer (AJCC) staging system. AJCC clinical N 
and M stage were not recorded, as the data points 
pertaining to lymphadenopathy and metastasis 
were selected for their previously demonstrated 
significance (9). Pretreatment albumin was not 
available for 11 of the 123 patients (8%) included 
in our study. Pretreatment LDH was not available 
in 81of 123 patients (65%). Although we chose to 
remove LDH from our primary analysis, a sensi-
tivity analysis was performed using multiple im-
putation to ensure no significant changes occur-
red due to missing data. Pretreatment risk factors 
used in our primary analysis were: serum albumin 
below laboratory normal range, clinical T3 or T4 
disease, presence of liver metastasis, symptomatic 
metastasis, and retroperitoneal or supradiaphrag-
matic lymphadenopathy >1cm. Survival data was 
gathered using available medical records and the 
Social Security death index. Our final query of the 
death index was on October 6, 2013.
Statistical analysis
Baseline patient characteristics
 Continuous variables were compared with 
the paired t-test, and categorical variables were 
compared with chi-squared testing. Statistical sig-
nificance was defined by p<0.05 (two-tailed).  
Median overall survival for CN patients stratified 
by risk factor group versus TT only.
 An attempt was made to validate the fin-
dings of Culp et al. in which they ascertained risk 
of death based on number of risk factors in CN 
patients (6). Therefore, CN patients were stratified 
by the number of pretreatment risk factors pre-
sent. TT patients were not subdivided and con-
sidered the referent for this analysis. Univariate 
Cox proportional hazards analysis was performed 
for each CN risk factor group and compared to all 
TT patients. Culp et al. conducted a Cox propor-
tional hazards analysis for CN patients with three 
or fewer and four or more risk factors. As LDH 
was removed from our analyses, the model was 
completed for CN patients with two or fewer risk 
factors and those with three or more risk factors.
Survival analysis
 Kaplan-Meier estimated overall survival 
(OS) was compared between CN and TT groups 
stratified by the number of pretreatment risk fac-
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Table 1 - Baseline patient clinical characteristics.
Variable CN TT p-value
Number of patients 88 35
Mean age (SD), years 57.4 (10.4) 57.8 (10.4) 0.87
Mean ACE score (SD) 1.22 (0.96) 1.26 (1.01) 0.83
Karnofsky performance ≤ 60 (%) 10/88 (11%) 12/35 (34%) <0.01
Mean number of risk factors (SD) 2.11 (1.17) 3.06 (1.08) <0.01
Albumin ≤ 3.5 (%), g/dL 61/88 (69%) 20/35 (57%) 0.20
Clinical stage ≥ T3 (%) 36/88 (41%) 13/35 (37%) 0.70
Liver metastasis (%) 18/88 (20%) 11/35 (31%) 0.20
Symptomatic metastasis (%) 47/88 (53%) 27/35 (77%) 0.02
Retroperitoneal LAD (%) 32/88 (36%) 19/35 (54%) 0.07
Supradiaphragmatic LAD (%) 26/88 (30%) 22/35 (63%) <0.01
CN = cytoreductive nephrectomy; TT = targeted therapy; SD = standard deviation; ACE = adult comorbidity evaluation; LAD = lymphadenopathy
tors present. As only one patient with fewer than 
two risk factors received TT alone without CN, 
all patients with fewer than two risk factors were 
excluded from the Kaplan-Meier analysis. There 
was no comparator group for patients with fewer 
than two risk factors receiving CN. The remaining 
patients were stratified into two groups: exactly 
two risk factors or three to five risk factors. Log 
rank p-values were calculated to compare survi-
val curves. Multivariate cox proportional hazar-
ds analysis was also performed adjusting for age 
and comorbidity.
Sensitivity analysis
 Multiple imputation analysis was perfor-
med for missing data. For each missing variable, 
multiple imputations were derived at random on 
the basis of the distribution of each variable wi-
thin our data. All statistical analyses were then 
repeated with imputed values for LDH and al-
bumin to ensure no changes resulted from mis-
sing data. All statistical analyses were comple-
ted using R software, version 2.15.1 using the 
package ‘survival’ for the survival analysis (10) 
and the package ‘MICE’ for multivariate imputa-
tion and analysis (11).
RESULTS
Baseline patient clinical characteristics are 
provided in Table-1. Mean number of risk factors 
was significantly greater for the TT group as com-
pared to the CN group (3.06±1.08 vs. 2.11±1.17, 
p<0.01). Significantly more patients in the TT 
group had symptomatic metastasis (77% vs. 53%, 
p=0.02) and supradiaphragmatic lymphadenopa-
thy (63% vs. 30%, p<0.01) as compared to the CN 
group. After CN, 14/88 (15.9%) CN patients did 
not undergo the previously planned TT; justifica-
tions included death (7.50%), refusal (2,14%), no 
evidence of disease (2, 14%), and decision in con-
sultation with medical oncology to undergo active 
surveillance (3,21%).
Figure-1 illustrates the distribution and 
frequency of individual risk factors stratified by 
the total number of risk factors present for each 
patient. For patients with exactly one risk factor, 
symptomatic metastasis was seen most frequen-
tly (17/22=77%). For patients with exactly two 
risk factors, symptomatic metastasis was also seen 
most frequently (24/42=57%), but all risk factors 
were represented. For patients with three or more 
factors, all risk factors were similarly represented: 
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clinical stage ≥T3 (32/53=60%), symptomatic me-
tastasis (33/53=62%), retroperitoneal lymphade-
nopathy (33/53=62%), and supradiaphragmatic 
lymphadenopathy (33/53=62%).
 Median OS for CN patients stratified by 
risk factor group compared to all TT patients are 
provided in Table-2. TT patients were not strati-
fied and served as the referent group. Patients who 
received TT alone without CN had a global median 
OS of 5.8 months. Patients who received CN and 
had two or fewer factors demonstrated median OS 
of 22.1 months. In univariate analysis, when com-
pared to all TT patients as a referent, this repre-
sented significantly greater OS (HR=0.39, 95% CI 
0.23-0.65). OS did not significantly differ between 
all TT patients and CN patients with three or more 
risk factors (HR=1.29, 95% CI 0.74-2.23).
 Table-3 demonstrates the median OS from 
our Kaplan-Meier analysis for both the CN and 
TT groups stratified by their number of risk fac-
tors. No patients in the TT group had zero risk 
factors, and only one had one risk factor. Due to 
this we were not able to carry out comparative 
analysis between CN patients with 0-1 risk factors 
and TT patients with 0-1 risk factors. Stratifica-
tion was performed to provide CN and TT groups 
with exactly two and three or more risk factors. 
Figure-2 illustrates the estimated survival curves 
for patients with exactly two risk factors. No sig-
nificant difference in median OS was noted be-
tween CN and TT only (447 vs. 389 days, p=0.24) 
for a difference of about 2 months. Figure-3 illus-
trates the estimated survival curves for patients 
with three or more factors. For these patients, no 
significant difference in median OS was noted be-
tween CN and TT only (184 vs. 155 days, p=0.87), 
for a difference of about 1 month. Furthermore, 
after stratification by number of risk factors pre-
sent and multivariate analysis controlling for age 
and comorbidities, CN did not demonstrate a be-
nefit in either those with exactly two risk factors 
(HR=1.37, 95% CI 0.56–3.38) or three or more risk 
factors (HR=0.87, CI 0.47–1.63).
 All analyses were repeated using the im-
puted values for LDH and albumin levels. The as-
sociation of increasing numbers of risk factors and 
worsening survival remained intact in this analy-
sis. CN was not associated with improvement in 
survival for patients with two or more risk factors 
in these analyses.
DISCUSSION
 We found that median overall survival for 
patients undergoing CN decreased as their num-
ber of preoperative risk factors increased. When 
the CN patients were stratified by preoperative 
risk factors and compared to the TT patient group 
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Table 2 - Median overall survival for CN patients stratified by risk factor group versus TT only.
Patient Group N HR 95% CI P-value Median OS, months
TT Only 35 Reference - - 5.8
CN 
Risk Factors 
0 6 0.47 0.11-1.99 0.30 15.5
1 21 0.30 0.15-0.63 <0.01 28.3
2 30 0.49 0.27-0.88 0.02 14.9
3 23 1.08 0.59-1.96 0.80 7.2
4 4 1.31 0.45-3.80 0.62 4.7
5 4 5.64 1.72-18.5 <0.01 2.0
< 2 57 0.39 0.23-0.65 <0.01 22.1
> 3 31 1.29 0.74-2.23 0.37 6.1
CN = cytoreductive nephrectomy; TT = targeted therapy; HR = hazard ratio; CI = confidence interval; OS = overall survival
Table 3 - Kaplan-Meier analysis with median overall survival for both the cytoreductive nephrectomy and targeted therapy 
groups stratified by number of risk factors.
Cytoreductive Nephrectomy Targeted Therapy
Factors Count Median Overall Survival (days) Count Median Overall Survival (days)
0 6 466.5 0 *
1 21 850 1 *
2 30 447 12 389
3 23 215 10 156
4 4 142.5 8 232
5 4 60.5 4 152
* = unable to calculate due insufficient data
as a whole, we found an apparent survival ad-
vantage for CN in patients with fewer than or 
equal to two risk factors (Table-2). However, af-
ter stratifying both CN and TT patients by the 
number of preoperative risk factors present, we 
found no differences in survival when exactly 
two or three or more pretreatment risk factors 
were present for each group, based on Kaplan-
-Meier analysis (Figures 2 and 3). Likewise, 
multivariate analysis controlling for age and 
ACE did not demonstrate a benefit of CN for 
patients with two or more risk factors.
 An attempt was made to validate the 
findings by Culp et al. in their analysis of 
risk factors in CN patients (Table-2) (6). Like 
the group from M.D. Anderson, we used the 
medical therapy cohort as the referent group. 
The noted difference in the present univariate 
analysis is that we were unable to include LDH 
as an assessed risk factor due to missing data in 
ibju | Risk stRatification and cytoReductive nephRectomy
437
colleagues, we stratified CN patients by two or 
fewer and three or more risk factors. Ultimate-
ly, our results mirror those of Culp et al. The 
analysis is challenging given the heterogeneity 
and inherent bias in the targeted therapy group, 
wherein nearly every patient had two or more 
risk factors. To account for these differences, we 
derived conclusions from Kaplan-Meier survival 
curves and multivariate Cox proportional ha-
zards models. In agreement with several other 
studies, we found the actual benefit of CN may 
be limited to a select patient population (6, 7, 
12). In cases where two or more risk factors were 
present, patients did not appear to benefit from 
CN in our stratified analysis.
 Interestingly, only a single patient with 
fewer than two risk factors received TT alone, 
highlighting a selection bias for patients under-
going CN versus receiving primary TT. In practi-
cal terms, it appears that urologists and medical 
oncologists are already selecting patients at hi-
ghest risk to forgo extirpative therapy. This seems 
to be largely based on intuition as our cohort lar-
gely predates the work by Culp et al. that defined 
these risk factors (6).
 Often, patients are unable to complete the 
planned medical therapy after CN. In the present 
cohort, 14/88 (15.9%) CN patients did not under-
go the intended TT. In 2010, Kutikov et al. publi-
shed their series of 141 patients who underwent 
CN (13). The authors found that 31% of patients 
did not undergo the intended systemic therapy. In 
this group, the medical therapy was omitted due 
to rapid disease progression (30%), decision for 
surveillance by oncology (21%), patient refusal 
(23%), and death (19%). Additionally, of the pa-
tients who did receive TT after CN, approxima-
tely half of the patients (33/69=47%) received a 
second-line TT due to either progression of disease 
or medication intolerability, and the decision of 
what medication to use as a second or third-line 
therapy was made at the discretion of the trea-
ting medical oncologist. Future studies with larger 
sample sizes may be able to identify patient and 
tumor factors predictive of the need for second or 
third-line TT.
 Previous population-based studies have 
demonstrated a benefit for patients treated with 
Figure 2 - Kaplan-Meier estimated survival comparing 
patients in cytoreductive nephrectomy group (CN) to 
targeted therapy group (TT) for patients with exactly two 
risk factors.
Figure 3 - Kaplan-Meier estimated survival comparing 
patients in cytoreductive nephrectomy group (CN) to 
targeted therapy group (TT) for patients with three to five 
risk factors.
a large portion of our cohort (65%). Also, in our 
preliminary analysis patients with three risk fac-
tors did not derive a benefit from CN. Therefore, 
rather than assess patients with three or fewer and 
four or more risk factors as was done by Culp and 
P-value = 0.243
P-value = 0.872
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CN (14-16). However, these population-based stu-
dies are not able to compare CN and TT patients 
with similar pretreatment risk factors. This inabi-
lity to accurately assess disease burden between 
treatment groups is a clear limitation. Furthermo-
re, many previous studies have included patients 
who received immunotherapy, presented with 
asynchronous metastasis, and received radiothe-
rapy (6, 14-16). Although our patient population 
is relatively small, we have removed many of the-
se confounding factors. The present study includes 
mRCC patients treated only in the TT era, with no 
treatment contamination with immunotherapy or 
radiotherapy. Additionally, we stratify not only 
our CN patients by pretreatment risk factors but 
also our TT patients as well. With both CN and 
primary TT patients stratified by number of risk 
factors, our study provides additional insight as 
to which patients may derive benefit from CN. For 
patients with exactly two and three to five risk 
factors, we found that performing CN prior to TT 
over TT alone provides minimal or no improve-
ment in survival. While our study is underpowe-
red to prove that this small survival improvement 
is statistically significant, even in an appropriate-
ly powered study this improvement must also be 
balanced with the known increased risk of surgi-
cal complications in mRCC patients (17).
 Our study is not without limitations. It is 
logical to assume based on our data that the per-
ceived overall health and corresponding progno-
sis of each patient biased the initial  treatments 
offered. Although the healthier patients, as judged 
by the surgeon, are more likely to receive CN, we 
found no evidence for improved survival over TT 
when data were analyzed stratified by the number 
of risk factors present. As stated previously, the 
overwhelming majority of patients with zero to 
one risk factor underwent CN at our institution, 
which prevents accurate comparisons between 
CN and primary TT in this lower risk patient po-
pulation. Although the TT alone group is a hete-
rogenous treatment group (receiving TKI, mTOR 
inhibitors, and VEGF inhibitors), the patients who 
were able to receive TT after CN were expected to 
have similar heterogeneity in their TT treatments. 
The choice of specific TT agents to use and when 
to withdraw or change therapy was made at the 
discretion of the treating medical oncologist and 
patient, and was not defined by an institutional 
or study protocol. While 15.9% of patients in the 
CN group did not complete the intended TT, this 
limitation is common in the literature (13). Fur-
thermore, the histologic subclassification in the TT 
alone group could not be determined as biopsies 
were performed on metastatic sites and limited 
in tissue. Future studies with larger sample sizes 
should examine the histologic subclassification of 
mRCC and identify if a strong association between 
histology and survival exists even when diagno-
sed at a metastatic stage. Finally, our results are 
from a tertiary care center, and may not reflect 
the full spectrum of metastatic RCC patients seen 
in community practice.
 Paramount to the practicing urologic sur-
geon is the relative weight of the risks and bene-
fits of CN. In a population-based series of 16,285 
patients by Trinh et al., the overall complication 
rate was 31% (17). Moreover, the complication 
rate was increased in those with numerous comor-
bidities and more than one metastatic site. Addi-
tionally, the in hospital mortality rate was 5%, 
and was significantly greater in those with age 
≥75 (7.9%), three or more comorbidities (7.7%), 
and two or more metastatic sites (7.4%). While 
the possible benefit of CN is enticing, the results 
presented herein show it may be prudent to forgo 
surgery in those with advanced disease or with 
significant medical illness. Avoiding costly com-
plications and untoward patient suffering is of vi-
tal concern.
CONCLUSIONS
 Using previously described preoperative 
risk factors we found that patients with two or 
more risk factors derived no significant survival 
advantage from CN in the TT era. These risk fac-
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